scholarly journals Development and fine-tuning of a scale down model for process characterization studies of a monoclonal antibody upstream production process

2011 ◽  
Vol 5 (S8) ◽  
Author(s):  
Mareike Harmsen ◽  
Jimmy Stofferis ◽  
Laetitia Malphettes
2021 ◽  
Vol 37 (4) ◽  
pp. 112-122
Author(s):  
A.N. Morozov ◽  
Z.V. Zakharov ◽  
S.V. Kalenov ◽  
R.A. Khamitov

According to generally accepted international standards, the characterization and confirmation of the quality of biological pharmaceutical substances requires the use of not only a combination of physicochemical and biological tests, but also an in-depth knowledge of the production process and its control. The study of such an industrial process involves considerable expenditure of time and material resources. Gaining a deep knowledge of the production process is greatly facilitated by using laboratory models of industrial installations that effectively reproduce large-scale processes in a research laboratory. On the basis of a laboratory bioreactor for the cultivation of eukaryotic cells with a working volume of 2 L, a scale-down model of a pilot bioreactor has been developed, linearly scalable to a production volume of 1000 L. The laboratory model reproduces the key parameters of cultivation on a pilot scale: the ratio of the geometric dimensions of the reactor, the peripheral speed of the mixer, the specific power input, the coefficient of oxygen mass transfer, the type and intensity of aeration, strategies for defoaming, feeding and maintaining the pH level. Experiments using the developed model showed high similarity in the kinetics of cell growth, productivity and quality of the expressed monoclonal antibodies in laboratory and pilot bioreactors. Key words: cultivation, CHO cells, monoclonal antibodies, scale-down model


2009 ◽  
Vol 55 (1) ◽  
pp. 31-36 ◽  
Author(s):  
Kenta Kitsuka ◽  
Kazuhiro Kaneda ◽  
Mineo Ikematsu ◽  
Masahiro Iseki ◽  
Katsuhiko Mushiake ◽  
...  

2009 ◽  
Vol 104 (6) ◽  
pp. 1107-1120 ◽  
Author(s):  
Rachel Legmann ◽  
H. Brett Schreyer ◽  
Rodney G. Combs ◽  
Ellen L. McCormick ◽  
A. Peter Russo ◽  
...  

2015 ◽  
Vol 113 (6) ◽  
pp. 1273-1283 ◽  
Author(s):  
Matthew G. Petroff ◽  
Haiying Bao ◽  
John P. Welsh ◽  
Miranda van Beuningen - de Vaan ◽  
Jennifer M. Pollard ◽  
...  

Author(s):  
MANI JANAKIRAM ◽  
J. BERT KEATS

Failure Mode and Effects Analysis (FMEA) is well-known as a useful tool in the design process. It is used by some engineers as part of process characterization studies. Yet FMEA is virtually ignored in most process quality improvement paradigms. We suggest its use in quality improvement programs and indicate where it belongs and how it can be applied.


BioTechniques ◽  
2021 ◽  
Vol 70 (2) ◽  
pp. 126-133
Author(s):  
Camila Hiromi Chiba ◽  
Marcos Camargo Knirsch ◽  
Adriano Rodrigues Azzoni ◽  
Antonio R Moreira ◽  
Marco Antonio Stephano

Biopharmaceutical products are of great importance in the treatment or prevention of many diseases and represent a growing share of the global pharmaceutical market. The usual technology for protein synthesis (cell-based expression) faces certain obstacles, especially with ‘difficult-to-express’ proteins. Cell-free protein synthesis (CFPS) can overcome the main bottlenecks of cell-based expression. This review aims to present recent advances in the production process of biologic products by CFPS. First, key aspects of CFPS systems are summarized. A description of several biologic products that have been successfully produced using the CFPS system is provided. Finally, the CFPS system's ability to scale up and scale down, its main limitations and its application for biologics production are discussed.


Sign in / Sign up

Export Citation Format

Share Document